Skip to main content

Table 1 Clinical characteristics and MRI features of patients

From: Better efficacy in differentiating WHO grade II from III oligodendrogliomas with machine-learning than radiologist’s reading from conventional T1 contrast-enhanced and fluid attenuated inversion recovery images

VariableODG2ODG3TotalP value
No. of patients, n191736NA
Location, n (%)0.378
 Frontal10/19 (52.6)10/17 (58.8)20/36 (55.6) 
 Temporal3/19 (15.8)5/17 (29.4)8/36 (22.2) 
 Parietal3/19 (15.8)1/17 (5.9)4/36 (11.1) 
 Insular1/19 (5.3)1/17 (5.9)2/36 (5.6) 
 Occipital0/19 (0)0/17 (0)0/36 (0) 
 Others2/19 (10.5)0/17 (0)2/36 (5.6) 
Gender, n (%)0.202
 Male8/19 (42.1)11/17 (64.7)19/36 (52.8) 
 Female11/19 (57.9)6/17 (35.3)17/36 (47.2) 
Age a0.788
 Mean ± SD45.6 ± 13.744.3 ± 15.145.0 ± 14.4 
Signal, n (%)0.092
 Homogeneous6/19 (31.6)1/17 (5.9)7/36 (19.4) 
 Heterogeneous13/19 (68.4)16/17 (94.1)29/36 (80.6) 
Tumor cross midline, n (%)1.000
 No16/19 (84.2)14/17 (82.4)30/36 (83.3) 
 Yes3/19 (15.8)3/17 (17.6)6/36 (16.7) 
Multiple foci, n (%)0.736
 No12/19 (63.2)9/17 (52.9)21/36 (58.3) 
 Yes7/19 (36.8)8/17 (47.1)15/36 (41.7) 
Necrosis, n (%)0.044*
 No13/19 (68.4)5/17 (29.4)18/36 (50.0) 
 Yes6/19 (31.6)12/17 (70.6)18/36 (50.0) 
Cyst, n (%)0.255
 No16/19 (84.2)11/17 (64.7)27/36 (75.0) 
 Yes3/19 (15.8)6/17 (35.3)9/36 (25.0) 
Edema, n (%)0.106
 No4/19 (21.1)0/17 (0)4/36 (11.1) 
 Yes15/19 (78.9)17/17 (100.0)32/36 (88.9) 
Border, n (%)1.000
 Sharp/smooth2/19 (10.5)1/17 (5.9)3/36 (8.3) 
 Indistinct/irregular17/19 (89.5)16/17 (94.1)33/36 (91.7) 
Enhancement, n (%)0.002*
 No/blurry15/19 (78.9)4/17 (23.5)19/36 (52.8) 
 Nodular/ring-like4/19 (21.1)13/17 (76.5)17/36 (47.2) 
Cognitive dysfunction, n (%)0.274
 No7/19 (36.8)3/17 (17.6)10/36 (27.8) 
 Yes12/19 (63.2)14/17 (82.4)26/36 (72.2) 
Epileptic seizures, n (%)1.000
 No10/19 (52.6)9/17 (52.9)19/36 (52.8) 
 Yes9/19 (47.4)8/17 (47.1)17/36 (47.2)